Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
NGO · Ireland
Industry association · Belgium
Declared costs: €1.5M+ a year · in the register since 2008
Medicinal products for human use · Compulsory licensing of patents in crisis situations
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Access to Medicines Ireland · filed 26 Apr 2021 · source
Access to Medicines Ireland (AMI) welcomes the opportunity to contribute to the revision of the general pharmaceutical legislation. We have comments, and recommendations in the following areas: Unmet Need 1. Towards a definition of ‘unmet need’, we recommend developing a fair, equitable and transparent decision-making process for what is an ‘unmet need’. 2.
American Chamber of Commerce to the EU · filed 27 Apr 2021 · source
The American Chamber of Commerce to the EU (AmCham EU) is committed to the development of a regulatory environment which furthers the capabilities of European healthcare, improving accessibility and ensuring a crisis-resistant medicines regulatory system.
American Chamber of Commerce to the EU · filed 6 Nov 2023 · source
Introduction To be truly future proof and innovation friendly, the EU's proposed pharmaceutical package must address the blocs declining attractiveness for investment. We therefore urge EU co-legislators to secure globally competitive incentives for research and development (R&D) and avoid additional unnecessary administrative burdens on companies.
American Chamber of Commerce to the EU · filed 6 Nov 2023 · source
Introduction To be truly future proof and innovation friendly, the EU's proposed pharmaceutical package must address the blocs declining attractiveness for investment. We therefore urge EU co-legislators to secure globally competitive incentives for research and development (R&D) and avoid additional unnecessary administrative burdens on companies.
Access to Medicines Ireland · filed 29 Apr 2022 · source
Compulsory Licensing in the EU: Call for Evidence Submission by Access to Medicines Ireland (AMI) 29 April 2022 [max 4000 characters] AMI is a voluntary membership group of Cómhlamh, and we welcome the opportunity to provide feedback on the EU’s proposal to review the compulsory licensing in Europe.
American Chamber of Commerce to the EU · filed 26 Jul 2023 · source
A predictable and reliable intellectual property system is necessary for companies to innovate. The existing systems of national compulsory licensing already create an appropriate IP environment, and an EU-wide Compulsory License would create unnecessary burdens for businesses.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.